Ind-Swift Laboratories Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹4.52 billion
- Book Value:
- Revenue TTM:
- ₹12.23 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹5.26 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ind-Swift Laboratories Limited had its IPO on under the ticker symbol INDSWFTLAB.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Ind-Swift Laboratories Limited has a staff strength of 1,452 employees.
Shares of Ind-Swift Laboratories Limited opened at ₹71.1 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹70.8 - ₹77.65, and closed at ₹76.35.
This is a +8.14% increase from the previous day's closing price.
A total volume of 936,267 shares were traded at the close of the day’s session.
In the last one week, shares of Ind-Swift Laboratories Limited have increased by +16.39%.
Ind-Swift Laboratories Limited's Key Ratios
Ind-Swift Laboratories Limited has a market cap of ₹4.52 billion, indicating a price to book ratio of 0.6323 and a price to sales ratio of 0.3572.
In the last 12-months Ind-Swift Laboratories Limited’s revenue was ₹12.23 billion with a gross profit of ₹5.26 billion and an EBITDA of ₹2.61 billion. The EBITDA ratio measures Ind-Swift Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ind-Swift Laboratories Limited’s operating margin was 8.13% while its return on assets stood at 0% with a return of equity of 0%.
In Q4, Ind-Swift Laboratories Limited’s quarterly earnings growth was a positive 71.6% while revenue growth was a positive 22.6%.
Ind-Swift Laboratories Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹2.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ind-Swift Laboratories Limited’s profitability.
Ind-Swift Laboratories Limited stock is trading at a EV to sales ratio of 1.1236 and a EV to EBITDA ratio of 5.3249. Its price to sales ratio in the trailing 12-months stood at 0.3572.
Ind-Swift Laboratories Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹18.17 billion
- Total Liabilities
- ₹3.42 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Ind-Swift Laboratories Limited ended 2023 with ₹18.17 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹18.17 billion while shareholder equity stood at ₹6.46 billion.
Ind-Swift Laboratories Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹3.42 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹138.68 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹8.11 billion.
Ind-Swift Laboratories Limited’s total current assets stands at ₹11.17 billion while long-term investments were ₹0 and short-term investments were ₹259.38 million. Its net receivables were ₹4.98 billion compared to accounts payable of ₹1.97 billion and inventory worth ₹4.54 billion.
In 2023, Ind-Swift Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Ind-Swift Laboratories Limited paid ₹0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ind-Swift Laboratories Limited stock is currently trading at ₹76.35 per share. It touched a 52-week high of ₹77.69 and a 52-week low of ₹77.69. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹63.93 and 200-day moving average was ₹62.49 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6778.1% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Ind-Swift Laboratories Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.